Therapeutic Drug Monitoring of Orally Administered Letermovir Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant Recipients-Reference-Cited by-同舟云学术

Therapeutic Drug Monitoring of Orally Administered Letermovir Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant Recipients

Published:2022-08-16 Issue:8 Volume:66 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Royston Léna¹^ORCID,Masouridi-Levrat Stavroula²,Gotta Verena³,Royston Eva²,Pressacco-Brossier Caroline¹,Abi Aad Yasmine¹,Tonoli David⁴,Karmime Abderrahim⁴,Jayo Murielle⁴,Van Delden Christian¹,Lescuyer Pierre⁴,Pfister Marc³,Chalandon Yves²,Neofytos Dionysios¹^ORCID

Affiliation:

1. Division of Infectious Diseases, University Hospital of Geneva, Geneva, Switzerland

2. Division of Hematology, Bone Marrow Transplant Unit, University Hospital of Geneva and Faculty of Medicine, University of Geneva, Geneva, Switzerland

3. Division of Pediatric Pharmacology and Pharmacometrics, University of Basel Children's Hospital, Basel, Switzerland

4. Division of Laboratory Medicine, University Hospital of Geneva, Geneva, Switzerland

Abstract

With balanced safety-efficacy profile, letermovir anti-cytomegalovirus (CMV) prophylaxis is used in hematopoietic stem cell transplant recipients (HSCTR). We assessed feasibility and usefulness of letermovir therapeutic drug monitoring (TDM) in HSCTR.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.00657-22

Reference25 articles.

1. The role of cytomegalovirus serostatus on outcome of hematopoietic stem cell transplantation

2. Risk Factors for Cytomegalovirus Infection after Human Marrow Transplantation

3. Economic burden of preemptive treatment of CMV infection after allogeneic stem cell transplantation: a retrospective study of 208 consecutive patients

4. Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies

5. Cytomegalovirus Reactivation Is Associated with Increased Risk of Late-Onset Invasive Fungal Disease after Allogeneic Hematopoietic Stem Cell Transplantation: A Multicenter Study in the Current Era of Viral Load Monitoring

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Refractory/Resistant Cytomegalovirus Infection in Transplant Recipients: An Update;Viruses;2024-07-05

2. Clinical Pharmacokinetics and Pharmacodynamics of Letermovir in Allogenic Hematopoietic Cell Transplantation;Clinical Pharmacokinetics;2024-07

3. Management of cytomegalovirus infection in allogeneic hematopoietic stem cell transplants;International Journal of Antimicrobial Agents;2023-08

4. Pharmacokinetic analysis driven letermovir dosing in pediatric hematopoietic cell transplantation patients with resistant CMV disease;Pediatric Transplantation;2023-07-19

5. CMV Infection After Letermovir Primary Prophylaxis Discontinuation in Allogeneic Hematopoietic Cell Transplant Recipients;Open Forum Infectious Diseases;2023-03-27